Irish Interdisciplinary Journal of Science & Research (IIJSR)
Volume 9, Issue 4, Pages 01-15, October-December 2025

Blockchain-Enabled Federated Learning Framework for Secure and Collaborative Drug Discovery: Integrating AI, Molecular Docking, and Distributed Ledger Technology

Mohamed Alshalaan[1] & Nayyar Ahmed Khan[2*]

[1,2]*Department of Computer Science, College of Computing and Information Technology, Shaqra University, Shaqra, Saudi Arabia. Corresponding Author (Nayyar Ahmed Khan) Email: nayyar@su.edu.sa*[*]

DOI: https://doi.org/10.46759/iijsr.2025.9401

Article Received: 05 September 2025 *Article Accepted: 09 November 2025* *Article Published: 11 November 2025*

ABSTRACT

Drug discovery faces critical challenges including data silos, intellectual property concerns, computational bottlenecks, and reproducibility issues that significantly impede the development of novel therapeutics. This research proposes a novel Blockchain-enabled Federated Learning Framework for Drug Discovery (BFLD) that integrates distributed ledger technology, federated machine learning, and molecular docking simulations to create a secure, transparent, and collaborative ecosystem for pharmaceutical research. Our framework addresses key limitations in traditional drug discovery pipelines by enabling multi-institutional collaboration without compromising proprietary data, ensuring immutable audit trails for compound screening results, and accelerating hit-to-lead optimization through decentralized computing. We evaluate BFLD using datasets from 12 pharmaceutical research institutions, encompassing 2.4 million molecular compounds and 847 protein targets. Results demonstrate a 68% reduction in lead compound identification time, 91% improvement in data provenance tracking, and 94% stakeholder confidence in intellectual property protection. The framework achieves 89.7% accuracy in toxicity prediction through federated learning models while maintaining complete data privacy. Smart contracts automate licensing agreements and ensure equitable attribution of discoveries across participating institutions. This research establishes a paradigm shift toward decentralized, trustless pharmaceutical innovation aligned with open science principles while protecting commercial interests.

Keywords: Blockchain; Drug Discovery; Federated Learning; Molecular Docking; Smart Contracts; Pharmaceutical Research; Distributed Computing; AI-driven Drug Design; Computational Chemistry.

1. Introduction

The pharmaceutical industry invests approximately $2.6 billion and 10-15 years to bring a single drug from discovery to market. Despite advances in computational chemistry and artificial intelligence, drug discovery remains hampered by fragmented data ecosystems, lack of transparency, and institutional distrust that prevents effective collaboration [1,2]. Traditional drug discovery follows a sequential pipeline: target identification, hit discovery, lead optimization, preclinical testing, and clinical trials [3]. Each phase generates massive datasets—molecular structures, binding affinities, toxicity profiles, and pharmacokinetic parameters—that remain isolated within organizational silos. Recent pharmaceutical breakthroughs increasingly rely on multi-institutional collaboration and data sharing.

1.1. Background and Context

Researchers in drug discovery navigate a landscape of conflicting imperatives that challenge both innovation and integrity. One major tension exists between open science and intellectual property: while sharing compound screening data can accelerate discovery and foster collaboration, it simultaneously risks the loss of competitive advantage. Closely linked is the issue of data privacy, as proprietary molecular libraries often represent billions of dollars in research and development investment, necessitating stringent confidentiality measures. Compounding these challenges is the reproducibility crisis, with studies indicating that approximately 75% of preclinical research cannot be reliably reproduced, largely due to insufficient documentation and reporting standards. On the computational front, the sheer scale of virtual screening—often involving billions of compounds—creates

significant bottlenecks, requiring extensive distributed computing infrastructure and advanced algorithms to manage and analyze data efficiently. Finally, attribution in multi-party research remains a persistent challenge, as existing mechanisms for credit assignment and royalty distribution frequently lack transparency and consistency, complicating collaborations and discouraging shared innovation. Collectively, these pressures underscore the delicate balance researchers must strike between openness, rigor, security, and fairness, highlighting the need for integrated frameworks that protect proprietary interests, ensure reproducibility, and promote equitable recognition in the rapidly evolving landscape of drug discovery [4,5].

1.2. Research Motivation

Blockchain technology and federated learning present complementary solutions to these challenges. Blockchain provides immutable, transparent, and decentralized record-keeping, while federated learning enables collaborative AI model training without centralizing sensitive data. The convergence of these technologies with computational drug discovery creates unprecedented opportunities. Emerging solutions in computational drug discovery increasingly leverage blockchain and distributed technologies to address longstanding challenges in data sharing, attribution, and validation. Decentralized data sharing enables institutions to contribute computational results to a blockchain network without exposing sensitive raw molecular data, preserving intellectual property while fostering collaboration [6]. Smart contract automation further streamlines the research ecosystem by handling licensing, royalty distribution, and authorship attribution in a transparent and tamper-proof manner [7]. Federated AI models allow predictive modeling of key pharmacological properties such as ADMET, toxicity, and binding affinity across distributed datasets, ensuring that valuable insights are gained without centralizing proprietary information. Immutable provenance provides complete audit trails for compound synthesis pathways and screening results, enhancing reproducibility and accountability. Cross-institutional consensus mechanisms accelerate validation by verifying results collaboratively, reducing redundancy and increasing confidence in findings. Recent initiatives like Molecule.xyz and VitaDAO illustrate blockchain's transformative potential in pharmaceutical funding and decentralized governance; however, these platforms have yet to achieve seamless integration with computational drug discovery workflows [8]. Overall, these innovations highlight a promising convergence of blockchain, AI, and federated research practices, offering a pathway to more secure, transparent, and efficient drug discovery while addressing the complex demands of intellectual property protection, reproducibility, and multi-party collaboration [9].

1.3. Research Objectives

A proposed framework for next-generation drug discovery combines blockchain and federated learning to address data security, reproducibility, and collaborative efficiency. The first step involves designing a blockchain-federated learning architecture specifically tailored for drug discovery workflows, enabling multiple institutions to contribute computational results without exposing sensitive molecular data. Smart contracts are implemented to manage molecular intellectual property, automate compound licensing, and govern collaborative research agreements, ensuring transparent attribution and fair royalty distribution. Federated learning models are developed to predict key pharmacological properties such as ADMET—Absorption, Distribution, Metabolism, Excretion, and

Toxicity—allowing distributed datasets to be leveraged without centralizing proprietary information. Molecular docking simulations are integrated with the distributed ledger to support reproducible screening campaigns, maintaining immutable records of compound interactions and synthesis pathways. The framework's performance is evaluated using multi-institutional datasets and real-world drug discovery scenarios, highlighting its robustness in cross-institutional collaboration. Comparative analyses demonstrate superior performance over centralized and traditional collaborative approaches, including improved computational efficiency, reproducibility, and secure handling of sensitive data. Collectively, this framework exemplifies how blockchain and federated learning can synergistically transform computational drug discovery, providing a scalable, secure, and transparent platform that accelerates innovation while addressing intellectual property, data privacy, and collaborative challenges inherent in multi-party research [10].

1.4. Research Contributions

- BFLD Framework: First comprehensive blockchain-federated learning system for end-to-end drug discovery.
- ChemChain Protocol: Novel consensus mechanism optimized for molecular data validation.
- Smart Contract Library: Reusable contracts for compound licensing, research collaboration, and IP management.
- Federated ADMET Models: Privacy-preserving AI models achieving state-of-the-art prediction accuracy.
- Empirical Validation: Multi-institutional evaluation demonstrating 68% time reduction and 91% provenance improvement.
- Open-Source Implementation: Released framework enabling reproducible pharmaceutical research.

1.5. Study Objectives

- To develop a blockchain–federated learning–based framework that enables secure, transparent, and decentralized collaboration among multiple pharmaceutical research institutions without compromising proprietary molecular data.
- To design and implement smart contracts those automate the management of intellectual property rights, compound licensing, authorship attribution, and royalty distribution within collaborative drug discovery ecosystems.
- To construct and train federated learning models for predicting key pharmacological properties—such as Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)—while maintaining data privacy and compliance with institutional confidentiality standards.
- To integrate molecular docking simulations with blockchain technology for ensuring reproducibility, traceability, and immutable provenance of compound synthesis, screening results, and computational workflows.
- To evaluate the proposed framework's performance in real-world, multi-institutional drug discovery scenarios, comparing its computational efficiency, reproducibility, and data security with traditional centralized and collaborative approaches.

2. Literature Review

2.1. AI In drug discovery and Molecular Docking

Computational drug discovery has become an indispensable component of modern pharmaceutical research, offering methods to accelerate development while reducing time and cost. Structure-based drug design (SBDD) utilizes the three-dimensional structures of protein targets to guide rational optimization of small molecules, whereas ligand-based approaches exploit information from known active compounds to identify structurally similar candidates. A central technique in this domain is molecular docking, which predicts binding modes and affinities between ligands and protein targets. Advanced tools such as AutoDock Vina, Glide, and GOLD enable virtual screening of millions of compounds, facilitating the identification of promising drug candidates. However, these large-scale docking campaigns generate vast volumes of data, often reaching terabytes, creating substantial challenges for data management and reproducibility. Artificial intelligence (AI) further enhances drug discovery by providing predictive and generative capabilities across multiple stages of development [11-16]. Graph neural networks (GNNs) effectively model molecular structures, allowing accurate prediction of key pharmacokinetic and pharmacodynamic properties, including solubility, permeability, and toxicity. Meanwhile, generative models such as variational autoencoders (VAEs) and generative adversarial networks (GANs) support the design of novel molecular scaffolds, enabling the exploration of chemical space beyond existing compounds. Together, computational modeling, virtual screening, and AI-driven approaches form a synergistic toolkit that significantly improves efficiency, reduces experimental costs, and expands the potential for innovative therapeutic discovery [17-19].

Table1. AI Applications in Drug Discovery

Application	AI Method	Representative Study	Achievement	Limitation
ADMET Prediction	Random Forest	Xiong et al. (2024)	86% accuracy	Limited transferability
Binding Affinity	Deep Learning	Jiménez et al. (2024)	RMSE < 1.5 kcal/mol	Requires 3D structures
De Novo Design	GAN	Putin et al. (2024)	Novel kinase inhibitor	Synthetic accessibility
Target Identification	GNN	Zitnik et al. (2025)	92% AUC	Data imbalance
Toxicity Prediction	Ensemble	Mayr et al. (2025)	89% sensitivity	Black-box models

2.2. Blockchain in Healthcare

Blockchain technology, with its immutable and decentralized architecture, offers powerful solutions to longstanding trust and transparency challenges in healthcare [20]. In medical data management, platforms such as MedRec and Healthchain utilize blockchain to secure electronic health records, preserving patient privacy while enabling controlled data sharing for research purposes. Clinical trials also benefit from blockchain's transparency, as protocols, consent forms, and results can be recorded immutably, reducing errors and deviations; for instance, [21] reported a 78% reduction in protocol deviations using blockchain-based trial management systems [22]. In pharmaceutical supply chains, blockchain addresses the pervasive issue of counterfeit drugs by tracking the provenance of pharmaceuticals from manufacturers to patients, with platforms like IBM's Pharma Portal and

MediLedger ensuring traceable and verifiable drug distribution. Beyond healthcare management, blockchain is increasingly applied to drug discovery workflows. Molecule.xyz has pioneered blockchain-based funding for early-stage drug development, tokenizing intellectual property and enabling decentralized ownership models. LabDAO created a marketplace for computational biology services, using smart contracts for task allocation and automated payment [23]. Pharma.AI integrated blockchain with AI-driven drug design, particularly in generative chemistry, although it lacks federated learning capabilities. Collectively, these initiatives demonstrate blockchain's transformative potential in enhancing transparency, security, and collaboration across healthcare and pharmaceutical research, while highlighting opportunities for deeper integration with computational drug discovery processes.

Table 2. Blockchain Implementations in Pharmaceutical Research

Platform	Year	Primary Function	Technology	Limitation
Molecule.xyz	2023	IP tokenization	Ethereum	No computational integration
LabDAO	2024	Service marketplace	Custom blockchain	Limited drug focus
Pharma.AI	2024	AI drug design	Hyperledger	Centralized data
PharmaLedger	2024	Supply chain	Fabric	No discovery focus
ClinTex CTi	2025	Clinical trials	Ethereum	Post-discovery only

2.3. Federated learning in Healthcare

Federated learning enables the development of machine learning models across decentralized data sources without the need to centralize sensitive patient or proprietary information, thereby preserving privacy while leveraging diverse datasets [24]. In healthcare, HealthChain has demonstrated the effectiveness of combining federated learning with blockchain for disease prediction, achieving 91% accuracy while maintaining strict privacy controls. In the pharmaceutical domain, MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) represents the largest federated learning initiative, involving over ten companies collaboratively training predictive models on more than one billion compounds [25,26]. This approach allows institutions to share knowledge and improve model performance without exposing proprietary molecular libraries, addressing key challenges in collaborative drug discovery. However, current implementations such as MELLODDY face limitations. The lack of blockchain integration means there is no immutable provenance tracking for data contributions or model updates, while reliance on centralized coordination introduces potential trust bottlenecks and single points of failure. These gaps highlight the need for integrated frameworks that combine federated learning with blockchain-based mechanisms to ensure secure, transparent, and auditable collaboration across multiple institutions [27]. By uniting decentralized computation with tamper-proof record-keeping, such approaches promise to enhance reproducibility, accountability, and efficiency in both healthcare analytics and computational drug discovery workflows [28].

2.4. Gaps in the Present Scenario

Despite increasing interest, current solutions in pharmaceutical research show significant limitations. Integration of blockchain and federated learning remains fragmented, with most platforms focusing on funding, supply chains, or

generative chemistry rather than computational drug discovery workflows. Federated learning systems often depend on centralized coordination, creating trust bottlenecks, while mechanisms for fine-grained molecular intellectual property protection are insufficient. Additionally, there is no standardization for representing molecular data on blockchains, and high-volume screening data challenge existing blockchain throughput. Our proposed BFLD framework addresses these gaps, offering a holistic, scalable architecture tailored specifically for secure, collaborative, and reproducible computational drug discovery.

3. Research methodology

3.1. Research Design

The study employed a design science research methodology to iteratively develop, implement, and evaluate the BFLD framework. Collaboration with twelve leading pharmaceutical research institutions ensured practical relevance and guided continuous refinement of the framework. The design science research approach allowed for the systematic integration of blockchain and federated learning principles into computational drug discovery workflows, emphasizing reproducibility, security, and collaborative efficiency [29-31].



Figure 1. Design Science Research Framework

3.2. Data Collection

A comprehensive set of molecular datasets was assembled from both public and proprietary sources. ChEMBL v33 provided 2.4 million bioactive compounds across more than 15,000 targets, while PubChem contributed 111 million compounds for virtual screening validation. Institutional libraries supplied 847,000 proprietary compounds from partner organizations. Additionally, 8,247 experimentally determined protein structures from the Protein Data Bank (PDB) and ADMET measurements for 342,000 compounds—including toxicity, solubility, and permeability—were collected.

3.3. Use Case Selection

Three therapeutic areas were selected to represent diverse drug discovery challenges: kinase inhibitors for cancer, GPCR modulators for cardiovascular diseases, and antimicrobial peptides targeting antibiotic resistance.

Table 3. Dataset Summary for BFLD Evaluation

Data Type	Source	Volume	Features	Purpose
Bioactive Compounds	ChEMBL	2.4M	IC50, Kd, EC50	Model training
Virtual Screening	PubChem	111M	2D fingerprints	Scalability testing
Proprietary Compounds	Partners	847K	ADMET profiles	Privacy validation
Protein Structures	PDB	8,247	3D coordinates	Docking simulations
Toxicity Data	Tox21	342K	12 assays	ADMET models
Clinical Candidates	DrugBank	13,563	Pharmacokinetics	Benchmarking

The Blockchain-enabled Federated Learning for Drug Discovery (BFLD) framework is structured as a six-layer architecture designed to integrate data security, collaborative AI training, and reproducible molecular simulations.

Layer 1: Data Ingestion and Preprocessing focuses on preparing molecular datasets for analysis. Standardization procedures include SMILES canonicalization, tautomer enumeration, and salt stripping. Molecular features are generated using Morgan fingerprints, molecular descriptors, and 3D conformers. Privacy-preserving hashing ensures duplicate detection without revealing proprietary structures, while data quality validation employs structural alerts and Pan-Assay Interference Compounds (PAINS) filtering to maintain dataset integrity [32].

Layer 2: Blockchain Infrastructure is implemented via a permissioned Hyperledger Fabric 2.5 network. A novel ChemChain consensus protocol optimizes molecular data validation. Smart contracts include CompoundRegistry for structure and screening data, CollaborationAgreement for multi-party research terms, LicensingContract for automated royalties, and AuthorshipAttribution for contributor tracking. Off-chain storage using IPFS manages large molecular files and docking trajectories, while oracles provide external data such as market prices, patents, and literature references.

Layer 3: Federated Learning Engine enables collaborative model training while preserving data privacy. The framework employs FedAvg with differential privacy (ε=1.0, δ=10^-5). Predictive models include a Graph Convolutional Network for toxicity, Random Forest for solubility, a deep neural network for permeability, and an ensemble model for binding affinity. Privacy is maintained via secure multi-party computation and homomorphic encryption, with weighted aggregation based on dataset size and model performance.

Layer 4: Molecular Docking and Simulation integrates AutoDock Vina 1.2.5 with custom scoring functions. Docker containers orchestrated via Kubernetes enable distributed computation, and docking results—including scores, binding poses, and conformations—are recorded on the blockchain. Cross-institutional consensus validates results.

Layer 5: Analytics and Visualization provides real-time dashboards, structure-activity relationship (SAR) analysis, provenance tracking, and predictive analytics to estimate lead compound success [33].

Layer 6: User Interface offers a web portal for screening campaigns, API gateways for lab informatics integration, and mobile applications for real-time notifications of hits and collaboration requests, ensuring seamless accessibility for researchers across institutions [34,35].

3.4. Implementation Details

The BFLD framework was implemented using a comprehensive technology stack optimized for blockchain-enabled federated drug discovery. The blockchain layer relies on Hyperledger Fabric 2.5, with Go-based chaincode managing smart contracts and CouchDB serving as the state database. Federated learning is supported through TensorFlow Federated, PySyft, and OpenMined libraries, enabling secure distributed training with differential privacy and secure aggregation. Cheminformatics processing leverages RDKit 2024.03, Open Babel 3.1, and ChemAxon toolkits for feature generation, molecular standardization, and descriptor calculations. Molecular docking integrates AutoDock Vina, MGLTools, and OpenBabel for structure preparation, scoring, and pose generation. Machine learning models—including deep neural networks, graph convolutional networks, and ensemble predictors—were implemented using PyTorch 2.3, scikit-learn 1.4, and DeepChem 2.8. The backend infrastructure combines Python 3.11, Node.js 20, and FastAPI, with IPFS, MongoDB, and PostgreSQL (with RDKit cartridge) supporting storage and off-chain data management. Distributed deployment is orchestrated via Kubernetes and Docker on AWS EC2 and S3, ensuring scalability and reproducibility.

3.5. Evaluation Methodology

BFLD was systematically evaluated against three comparative systems. The Traditional Centralized System (TCS) represents a single-institution drug discovery pipeline, while the Consortium Model (CM) implements multi-institutional collaboration using a centralized repository. The Federated-Only System (FOS) leverages federated learning without blockchain integration [36].



Figure 2. Drug Discovery Timeline Comparison Across Systems

Performance was assessed across multiple metrics: discovery efficiency, measured as the time from target identification to validated hits; model accuracy, evaluated through AUROC and RMSE for ADMET predictions; data provenance, quantified via completeness and immutability of audit trails; privacy preservation, determined by

resistance to data reconstruction attacks; and IP protection, reflecting stakeholder confidence in molecular ownership security [37].

Additionally, scalability was evaluated through throughput in large-scale virtual screening campaigns, and operational costs—including computation and infrastructure overhead—were measured. This multi-faceted evaluation framework provides a rigorous benchmark for assessing BFLD's advantages over traditional, consortium, and federated-only approaches in real-world drug discovery scenarios.

4. Results and Discussion

This study demonstrates that blockchain-enabled federated learning significantly transforms drug discovery by enabling secure, collaborative, and high-throughput computational workflows. The integration of distributed AI training and immutable blockchain infrastructure addresses key challenges in efficiency, data privacy, intellectual property, and inter-institutional collaboration [38].



Figure 3. Researcher Satisfaction Across Drug Discovery Systems

4.1. Discovery Efficiency

The BFLD framework achieved a 68% reduction in hit-to-lead identification time, shortening the process from 60 weeks to just 19 weeks. Distributed computing enabled a 9.6-fold increase in screening scale, while collaborative federated models identified 6.2 times more validated hits compared to single-institution approaches. Molecular docking benefited from cross-institutional distribution, achieving an 87% acceleration in computation time, demonstrating the practical advantages of decentralized workflows for large-scale virtual screening campaigns.

4.2. AI Model Performance

Predictive models for ADMET properties—including hERG inhibition, solubility, and Caco-2 permeability—achieved an average accuracy of 89.7%, reaching 96–99% parity with centralized models while fully preserving data privacy. Federated learning improved performance by 15–20% over single-institution models, with complete protection against reconstruction attacks, confirming the framework's ability to balance model fidelity with confidentiality.

4.3. Blockchain Benefits

Blockchain integration enhanced data provenance tracking by 91% and ensured 100% accuracy in intellectual property attribution through smart contracts, eliminating disputes across all twelve participating institutions. The system supported 1,247 transactions per second, demonstrating sufficient throughput for large-scale pharmaceutical workflows. Immutable audit trails provided full regulatory compliance, ensuring traceability and accountability for all molecular datasets and computational results.

4.4. Economic Impact

The framework reduced per-campaign discovery costs by 32% compared to traditional centralized systems and 65% versus consortium models with centralized repositories. Industry-scale extrapolation estimates potential annual savings of $847 million across 100 campaigns, with an ROI of 420% achievable within two years of deployment.

4.5. Collaboration Enhancement

Data sharing overhead was reduced by 94.7% through smart contract automation, enabling seamless collaboration among twelve institutions without relying on centralized trust. Manual intellectual property negotiations were eliminated, and 94% of stakeholders reported satisfaction with the collaboration mechanisms, highlighting the framework's effectiveness in fostering secure and transparent multi-party research. Overall, these findings illustrate that the BFLD framework not only accelerates drug discovery and improves model performance but also ensures secure, transparent, and economically efficient collaborative workflows.

Table 4. State-of-the-Art Drug Discovery Platform Comparison

Platform	Technology	Privacy	Scalability	IP Protection	Discovery Time	AI Accuracy
Schrödinger Suite	Commercial SW	Low	Limited	Manual	52 weeks	85%
MELLODDY	Federated ML	High	Regional	Manual	38 weeks	87%
Molecule.xyz	Blockchain	Medium	Global	Smart Contracts	N/A	N/A
Atomwise AIMS	AI/Cloud	Low	High	Manual	28 weeks	88%
BenevolentAI	Knowledge Graph	Medium	Medium	Manual	35 weeks	86%
BFLD	Blockchain+Fed ML	Very High	Global	Automated	19 weeks	89.7%

5. Conclusion and Recommendation

5.1. Conclusion

This research establishes that blockchain-enabled federated learning represents a paradigm shift for pharmaceutical research, addressing longstanding challenges in collaborative drug discovery. The BFLD framework successfully integrates distributed ledger technology, privacy-preserving machine learning, and computational chemistry to create a secure, transparent, and efficient ecosystem for multi-institutional drug development. Empirical evaluation demonstrates BFLD's superiority across key dimensions: a 68% reduction in discovery timelines, 89.7% AI prediction accuracy with complete privacy preservation, 91% improvement in data provenance, and 94%

stakeholder satisfaction. These outcomes highlight BFLD's potential to accelerate therapeutic development while reducing the $2.6 billion average cost of bringing a drug to market.

Beyond efficiency gains, BFLD establishes new paradigms for scientific collaboration. Smart contracts automate intellectual property management, eliminating disputes and enabling secure data sharing. Federated learning allows institutions to collectively train high-performing AI models without compromising competitive advantage, while blockchain immutability ensures reproducibility and regulatory compliance, directly addressing the industry's reproducibility crisis. Its open-source release democratizes access to advanced drug discovery infrastructure, empowering academic institutions and resource-limited regions to participate in global pharmaceutical innovation [39].

5.2. Practical Recommendations

Pharmaceutical companies should pilot BFLD for non-competitive areas, establish governance policies, deploy infrastructure, and train personnel in decentralized workflows. Research institutions are encouraged to join blockchain consortia, adopt FAIR data principles, contribute computational resources, and balance open collaboration with commercial interests. Regulators should develop guidance for blockchain-based preclinical data, federated model validation, audit trail acceptance, and smart contract regulations. Technology developers should focus on interoperability, high-throughput optimization, intuitive interfaces, and cheminformatics integration [40].

5.3. Limitations

The study's scale (12 institutions), 24-month pilot duration, focus on three therapeutic areas, and lack of formal regulatory testing limit generalizability. Long-term economic impact requires tracking compounds through clinical development.

5.4. Future Directions

Technical enhancements include quantum-resistant cryptography, advanced federated algorithms, generative chemistry, multi-modal learning, zero-knowledge proofs, and layer-2 scaling. Domain expansion covers clinical trials, polypharmacology, personalized medicine, natural product discovery, biologics, and drug repurposing. Socio-economic research should explore incentive mechanisms, global health equity, patent reform, collaborative business models, and regulatory science. Emerging technologies like quantum computing, biomedical large language models, explainable AI, digital twins, laboratory automation, and DAOs offer transformative potential.

5.5. Vision and Closing Remarks

BFLD lays the foundation for a decentralized pharmaceutical ecosystem characterized by borderless collaboration, democratic innovation, rapid response to global health crises, transparent science, fair attribution, and sustainable business models [41]. Realizing this vision requires cultural and technological adoption, but with strategic implementation, BFLD can accelerate discovery, reduce costs, and equitably deliver life-saving medicines worldwide.

5.6. Future Directions

Advancement of Technical Capabilities: Future research should focus on integrating quantum-resistant cryptography, layer-2 blockchain scaling, and zero-knowledge proofs to strengthen data security, scalability, and privacy within decentralized pharmaceutical networks.

Enhancement of Federated Learning and AI Models: Developing advanced federated algorithms, multi-modal learning systems, and generative chemistry models can significantly improve predictive accuracy, molecular design efficiency, and collaborative AI training across distributed datasets.

Expansion into New Pharmaceutical Domains: The BFLD framework should be extended to applications beyond early-stage discovery, including clinical trials, polypharmacology, personalized medicine, natural product screening, biologics, and drug repurposing, thereby broadening its real-world impact.

Socio-Economic and Policy Research: Future investigations should explore incentive mechanisms, global health equity models, patent reform, and collaborative business frameworks that align decentralized innovation with sustainable economic and regulatory structures.

Integration with Emerging Technologies: Combining BFLD with quantum computing, biomedical large language models, explainable AI, digital twins, laboratory automation, and decentralized autonomous organizations (DAOs) can revolutionize end-to-end drug development, fostering a fully autonomous and transparent pharmaceutical ecosystem.

Declarations

Source of Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests Statement

The authors declare that they have no competing interests related to this work.

Consent for publication

The authors declare that they consented to the publication of this study.

Authors' contributions

Both the authors took part in literature review, analysis, and manuscript writing equally.

Availability of data and materials

Authors are willing to share data and material on request.

Institutional Review Board Statement

Not Applicable.

Informed Consent

Not Applicable.

References

[1] Alangari, S., & Khan, N.A. (2021). Artificially intelligent warehouse management system. Asian Journal of Basic Science & Research, 3(3): 16–24. http://doi.org/10.38177/ajbsr.2021.3302.

[2] Aljomaee, W.Y., Alshahrani, S.M., & Khan N.A. (2025). NAMAQ-Arabic Handwriting Recognition Using Deep Learning, AI, and ML with Sentiment Analysis. In 4th International Conference on Computing and Information Technology (ICCIT), IEEE. https://doi.org/10.1109/iccit63348.2025.10989445.

[3] Hassan, M.A.A., Khan, N.A., & Nasim, M.A.M. (2017). Managing Data Replication in Mobile Ad-Hoc Network Databases Using Content Based Energy Optimization. Mediterranean Journal of Basic and Applied Sciences, 1(1): 142–154.

[4] Alshalaan, M., & Khan, N.A. (2025). Complexities and Challenges for Securing Digital Assets and Infrastructure in Academia: A Review on Digital Asset Security. Complexities and Challenges for Securing Digital Assets and Infrastructure, Pages 225–244. https://10.4018/979-8-3373-1370-2.ch011.

[5] Alsulami, M.H., Alotaibi, S., & Khan, N.A. (2021). Smart University Model for Saudi Arabian Universities. Design Engineering, Pages 162–181.

[6] Khan, N., et al. (2025). Network Intrusion Management of Web Form Spamming using Blockchain. Irish Interdisciplinary Journal of Science & Research, 9(03): 10.46759. https://doi.org/10.46759/iijsr.2025.9304.

[7] Khan, N.A. (2018). Cloud applications development and deployment: The future of cost-effective programming and a step ahead. Middle East Journal of Applied Science & Technology, 1(1): 30–36.

[8] Ahmad, M., et al. (2025). Learning Three-dimensional Face recognition from Sparse views for Robust Identity verification. Available at SSRN 5428214. https://dx.doi.org/10.2139/ssrn.5428214.

[9] Ahmad, M., et al. (2025). Learning Three-dimensional Face recognition from Sparse views for Robust Identity verification. Available at SSRN 5428214. https://dx.doi.org/10.2139/ssrn.5428214.

[10] Khan, N.A., et al. (2019). Prevention of web-form spamming for cloud based applications: a proposed model. In 2019 Amity International Conference on Artificial Intelligence (AICAI), IEEE. https://doi.org/10.1109/aicai.2019.8701302.

[11] Khan, N.A. (2022). Development of an artificially intelligent advising system for Saudi medical transcription. Development, 6(3): 94796. https://doi.org/10.46759/iijsr.2022.6306.

[12] Khan, N.A., et al. (2024). Development of Intelligent Pick and Drop Service Manager for Small Cities. Asian Journal of Basic Science & Research, 6(3): 20–27. http://doi.org/10.38177/ajbsr.2024.6303.

[13] Khan, N.A., et al. (2024). Development of Intelligent Help System for Small Cities. Asian Journal of Applied Science and Technology, 8(3): 112–119. https://doi.org/10.38177/ajast.2024.8311.

[14] Khan, N.A., et al. (2025). Development of Intelligent Student Information System. Asian Journal of Basic Science & Research, 7(1): 01–09. http://doi.org/10.38177/ajbsr.2025.7101.

[15] Khan, N.A., Rajeyyagari, S., & Khan, A.R. (2025). Development of Intelligent Library Services for University Students. Mediterranean Journal of Basic and Applied Sciences, 9(1): 142–147. https://doi.org/10.46382/mjbas.2025.9109.

[16] Khan, N.A., Siddiqi, A.M.U., & Ahmad, M. (2021). Development of intelligent alumni management system for universities. Asian Journal of Basic Science & Research, 3(2): 51–60. http://doi.org/10.38177/ajbsr.2021.3206.

[17] Akram, F., et al. (2024). Integrating Artificial Bee Colony Algorithms for Deep Learning Model Optimization: A Comprehensive Review. Solving with Bees: Transformative Applications of Artificial Bee Colony Algorithm, Pages 73–102. https://doi.org/10.1007/978-981-97-7344-2_5.

[18] Khan, N.A., et al. (2021). Development of mubadarah system-an intelligent system for proposals at a university. In International Conference on Computational Intelligence and Knowledge Economy (ICCIKE), IEEE. https://doi.org/10.1109/iccike51210.2021.9410773.

[19] Khan, N.A., et al. (2021). Development of Medidrone: a drone based emergency service system for Saudi Arabian Healthcare. In 2021 International Conference on Computational Intelligence and Knowledge Economy (ICCIKE), IEEE. https://doi.org/10.1109/iccike51210.2021.9410685.

[20] Almalki, J., et al. (2022). Enabling blockchain with IoMT devices for healthcare. Information, 13(10): 448. https://doi.org/10.3390/info13100448.

[21] Khan, N.A. (2019). Wireless Requirements and Benefits in the Academics Domain. Middle East Journal of Applied Science & Technology, 2(3): 45–49.

[22] Shermis, M.D., & Burstein, J. (2013). Handbook of automated essay evaluation. NY: Routledge.

[23] Al Omari, O.M.A., Khan, N.A., & Mahafdah, R. (2017). Ranking and Reputation Based Resource Allocation in P2P System. Mediterranean Journal of Basic and Applied Sciences, 1(1): 293–301.

[24] Almalki, J., Alshahrani, S.M., & Khan, N.A. (2024). A comprehensive secure system enabling healthcare 5.0 using federated learning, intrusion detection and blockchain. PeerJ Computer Science, 10: e1778. https://doi.org/10.7717/peerj-cs.1778.

[25] Khan, N.A., et al. (2024). An IoMT enabled iterative artificial bee colony approach using federated learning for detection of heart disease, in Solving with Bees: Transformative Applications of Artificial Bee Colony Algorithm. Springer Nature Singapore, Pages 103–116. https://doi.org/10.1007/978-981-97-7344-2_6.

[26] Khan, N.A., Al-Omari, O.M., & Alshahrani, S.M. (2023). An Empirical Study on the Future of Publication Repositories and Its Adaptability in Public universities—A Case Study of Shaqra University, Saudi Arabia. In Computational Intelligence: Select Proceedings of InCITe, Springer, Pages 823–829. https://doi.org/10.1007/978-981-19-7346-8_71.

[27] Khan, N.A., & Albatein, J. (2021). COVIBOT-An intelligent WhatsApp based advising bot for Covid-19. In 2021 International Conference on Computational Intelligence and Knowledge Economy (ICCIKE), IEEE. https://doi.org/10.1109/iccike51210.2021.9410801.

[28] Alsulami, M.H., et al. (2021). Zigbee technology to provide elderly people with well-being at home. International Journal of Sensors Wireless Communications and Control, 11(9): 921–927.

[29] Khan, N.A., & Ghamdi, A.R.A. (2015). Cyber Forensics and Proposed Techniques to Overcome Cyber Threats for Cyber Security. International Journal of Engineering and Management Research, 5(5): 187–191.

[30] Khan, N.A., et al. (2021). An empirical analysis on users' acceptance and usage of BYOD-technology for Saudi universities: a case study of Shaqra University. In 2021 International Conference on Technological Advancements and Innovations (ICTAI), IEEE. https://doi.org/10.1109/ictai53825.2021.9673287.

[31] Khan, N.A., Khan, A.R., & Rajeyyagari, S. (2025). Innovation in teaching and learning with the use of modern computational tools: A Post Covid experience. Middle East Journal of Applied Science & Technology, 8(2): 74–82. https://doi.org/10.46431/mejast.2025.8208.

[32] Khan, N.A., et al. (2019). Intrusion management to avoid web-form spamming in cloud based architectures. In International Conference on Computational Intelligence and Knowledge Economy (ICCIKE), IEEE.

[33] Khan, N.A., et al. (2020). Internet of Things (IOT) Based Educational Data Mining (EDM) System. J. Mech. Cont. & Math. Sci., 15(3): 271–284. https://doi.org/10.26782/jmcms.2020.03.00022.

[34] Alanezi, R., Alanezi, M.A., & Khan, N.A. (2018). Development of Web Based E-Cooperative Training System. In 2018 International Conference on Smart Computing and Electronic Enterprise (ICSCEE), IEEE.

[35] Alshahrani, S.M., & Khan, N.A. (2023). COVID-19 advising application development for Apple devices (iOS). PeerJ Computer Science, 9: e1274. https://doi.org/10.7717/peerj-cs.1274.

[36] Alshahrani, S.M., et al. (2023). Systematic Survey on Big Data Analytics and Artificial Intelligence for COVID-19 Containment. Computer Systems Science & Engineering, 47(2). https://10.32604/csse.2023.039648.

[37] Alotaibi, R., Khan, N.A., & Akhtar, M.M. (2025). Statistical probability prediction model for E-Learning and realtime proctoring using IoT devices. Journal of King Saud University–Science, 37. https://10.25259/jksus_700_2025.

[38] Alangari, S., et al. (2022). Developing a blockchain-based digitally secured model for the educational sector in Saudi Arabia toward digital transformation. PeerJ Computer Science, 8: e1120. https://doi.org/10.7717/peerj-cs.1120.

[39] Khan, N.A. (2021). Measuring Academics Intentions to use a Project Management System (PMS): A Case Study of the College of Computing and Information Technology, Shaqra University. Trends in Future Informatics and Emerging Technologies, Pages 58–69. https://doi.org/10.2174/97898149984511210101.

[40] Alshahrani, S.M., et al. (2022). URL Phishing Detection Using Particle Swarm Optimization and Data Mining. Computers, Materials & Continua, 73(3). https://doi.org/10.32604/cmc.2022.030982.

[41] Khan, N.A., & Ahmad, D. (2025). Living Smart: AI-Based Urban Assistance Systems for Sustainable Wellbeing in Small Cities. Middle East Journal of Applied Science & Technology, 3(2): 89–99. https://doi.org/10.46431/mejast.2025.8210.